If Covid only becomes endemic there's still a place for treatments. If it's comparable to influenza leronlimab still has a role. Influenza mortality in the 2017-2018 flu season was 61,000 in the U.S. and around 400,000 to 600,000 worldwide. Many multiples of that must have been hospitalized. If there's a quarter million hospitalizations every year for severe/critical Covid in the U.S. and the same amount for influenza which leronlimab will also treat that's still a lot of patients.